Form 4 for ALNY ALNYLAM PHARMACEUTICALS, INC.
Accepted 2026-03-02 00:00:00 ET · period of report 2026-02-27 · accession 0001735276-26-000038 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-02 | 2026-02-27 | ALNY | Garg Pushkal | EVP Chief R, D | M - OptEx | $0.00 | +1,908 | 26.8K | +8% | $0 |
| DM | 2026-03-02 | 2026-02-27 | ALNY | Garg Pushkal | EVP Chief R, D | S - Sale+OE | $331.34 | -4,627 | 22.1K | -17% | -$1.53M |
| D | 2026-03-02 | 2026-02-27 | ALNY | Garg Pushkal | EVP Chief R, D | M - OptEx | $0.00 | -1,908 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-27 | M | A | 1,908 | $0.00 | 26,756 | D | — | — | |
| 2 | Common | Common Stock | 2026-02-27 | S | D | 127 | $328.92 | 26,629 | D | — | — | (F2) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $328.90 to $329.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 3 | Common | Common Stock | 2026-02-27 | S | D | 2,259 | $330.73 | 24,370 | D | — | — | (F3) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $330.08 to $331.05. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 4 | Common | Common Stock | 2026-02-27 | S | D | 1,159 | $331.49 | 23,211 | D | — | — | (F4) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $331.09 to $332.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 5 | Common | Common Stock | 2026-02-27 | S | D | 942 | $332.48 | 22,269 | D | — | — | (F5) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $332.11 to $333.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 6 | Common | Common Stock | 2026-02-27 | S | D | 140 | $334.39 | 22,129 | D | — | — | |
| 7 | Derivative | Restricted Stock Units | 2026-02-27 | M | D | 1,908 | $0.00 | 0 | D | — · — to — | 1,908 Common Stock | (F8) These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. (F9) On February 27, 2023, the reporting person was granted 5,724 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2026, the third and final tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4. (F10) The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date. |